Monitoring strategies for management of ART in children

The Lancet

Volumn 381, Issue 9875, 2013, Pages 1343-1344

  Kuhn, Louise ^a   Coovadia, Hoosen M ^b,c  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; LOPINAVIR; NEVIRAPINE; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CHILD; COMORBIDITY; DISEASE COURSE; DRUG EFFICACY; DRUG MONITORING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; NOTE; PRIORITY JOURNAL; PROBABILITY; REPRODUCIBILITY; SURVIVAL; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS LOAD;

EID: 84876291016     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60284-6     Document Type: Note

References (13)

1. ARROW Trial team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet 2013; published online March 7. http://dx.doi.org/10.1016/S0140-6736(12)62198-9.
2. Joint UN Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic. Geneva: Joint UN Programme on HIV/AIDS, 2012.
3. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359: 2233-44.
4. Mugyenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375: 123-31.
5. HIV Paediatric Prognostic Markers Collaborative Study. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS 2006; 20: 1289-94.
6. Mermin J, Ekwaru JP, Were W, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ 2011; 343: d6792.
7. Reynolds SJ, Sendagire H, Newell K, et al. Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda. BMC Infect Dis 2012; 12: 381.
8. Oliveira R, Krauss M, Essama-Bibi S, et al. Viral load predicts new world health organization stage 3 and 4 events in HIV-infected children receiving highly active antiretroviral therapy, independent of CD4 T lymphocyte value. Clin Infect Dis 2010; 51: 1325-33.
9. Walensky RP, Ciaranello AL, Park JE, Freedberg KA. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis 2010; 51: 85-92.
10. Shearer WT, Quinn TC, LaRussa P, et al, for the Women and Infants Transmission Study Group. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N Engl J Med 1997; 336: 1337-42.
11. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363: 1510-20.
12. Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366: 2380-89.
13. Frohoff C, Moodley M, Fairlie L, et al. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One 2011; 6: e17273.